
Mindstate Design Labs is developing drugs that aim to deliver psychedelic benefits without a trip, drawing funding from Y Combinator and the founders of OpenAI, Neuralink, Instacart (NASDAQ:CART), Coinbase (NASDAQ:COIN), and Twitch, according to Wired.
The company built Osmanthus, an AI platform that links biochemical profiles of psychoactive compounds to more than 70,000 human trip reports from sources that include clinical datasets, forums, social media, Reddit (NYSE:RDDT), and the dark web, Wired reported.